Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia

References

• Weiden PJ. Switching antipsychotics: an updated review with a focus on quetiapine. J Psychopharmacol 2005;20:104–18
   PubMed Web of Science ®Google Scholar
• Tandon R, Jibson MD. Comparing efficacy of first-line atypical antipsychotics: no evidence of differential efficacy between risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole. Int J Psychiatry Clin Pract 2005;9:204–12
   PubMed Web of Science ®Google Scholar
• Edlinger M, Baumgartner S, Eltanaihi-Furtmuller N, et al. Switching between second-generation antipsychotics: why and how? CNS Drugs 2005;19:27–42
   Google Scholar
• Covell NH, Jackson CT, Evans AC, et al. Antipsychotic prescribing practices in Connecticut’s public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 2002;28:17–29
   PubMed Web of Science ®Google Scholar
• Leslie DL, Rosenheck RA. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. Am J Psychiatry 2002;159:1534–40
   PubMed Web of Science ®Google Scholar
• Rothbard AB, Kuno E, Foley K. Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophr Bull 2003;29:531–40
   Google Scholar
• Fleischhacker WW, Oehl MA, Hummer M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 2003;64(Suppl 16):10–3
   Google Scholar
• Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 2006;67(Suppl 5):3–8
   PubMed Web of Science ®Google Scholar
• Cheer SM, Wagstaff AJ. Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs 2004;18:173–99
   PubMed Web of Science ®Google Scholar
• Arvanitis LA, Miller BG, the Seroquel Trial 13 study group. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42: 233–46
   Google Scholar
• Kahn RS, Schulz SC, Palazov VD, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:832–42
   PubMed Web of Science ®Google Scholar
• Peuskens J, Trivedi J, Malyarov S, et al. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: A randomized, placebo-controlled trial in clinically stable patients. Psychiatry (Edgemont) 2007; 4(11):34–50
   PubMedGoogle Scholar
• Guy W. ECDEU assessment manual for psychopharmacology. Rockville MD: US National Institute of Health, 1976
   Google Scholar
• Voruganti LN, Awad AG. Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res 2002;56:37–46
   PubMed Web of Science ®Google Scholar
• Holm S. A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics 1979;6:65–70
   Web of Science ®Google Scholar
• Borison RL, Arvanitis LA, Miller BG, the US Seroquel Study Group. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16: 158–69
   Google Scholar
• Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54:549–57
   Google Scholar
• De Nayer A, Windhager E, Irmansyah, et al. Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. Int J Psychiatry Clin Pract 2003;7:59–66
   PubMed Web of Science ®Google Scholar
• Still DJ, Dorson PG, Crismon ML, et al. Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatr Serv 1996;47:1382–4
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Simpson GM, Potkin SG, et al. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 2003;64:580–8
   PubMed Web of Science ®Google Scholar
• Conley RR, Tamminga CA, Kelly DL, et al. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiatry 1999;46:73–7
   PubMed Web of Science ®Google Scholar
• Dossenbach MRK, Beuzen J-N, Avnon M, et al. The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. Clin Ther 2000;22:1021–34
   Google Scholar
• Dossenbach MRK, Kratky P, Schneidman M, et al. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. J Clin Psychiatry 2001;62(Suppl 2):28–34
   PubMed Web of Science ®Google Scholar
• Lee CT, Conde BJL, Mazlan M, et al. Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific. J Clin Psychiatry 2002;63:569–76
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Czobor P, Volavka J, et al. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. J Clin Psychiatry 2002;63:931–5
   PubMed Web of Science ®Google Scholar
• Littrell KH, Johnson CG, Hilligoss NM, et al. Switching clozapine responders to olanzapine. J Clin Psychiatry 2000;61:912–5
   PubMed Web of Science ®Google Scholar
• Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 2007;164:415–27
   PubMed Web of Science ®Google Scholar